IBT
ALXN

International Biotechnology Trust’s Alexion Pharmaceuticals ALXN Stock Holding History

International Biotechnology Trust’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-99,241
Closed -$15.5M – 59
2020
Q4 		$15.5M Buy
99,241
+24,000
+32% +$3.08M 4.23% 10
2020
Q3 		$8.6M Sell
75,241
-13,000
-15% -$1.4M 2.78% 14
2020
Q2 		$9.81M Buy
88,241
+14,600
+20% +$1.55M 3.26% 13
2020
Q1 		$6.61M Sell
73,641
-12,500
-15% -$1.23M 3.01% 13
2019
Q4 		$9.31M Sell
86,141
-16,000
-16% -$1.71M 3.35% 10
2019
Q3 		$10M Buy
102,141
+3,500
+4% +$395K 4.62% 7
2019
Q2 		$12.9M Buy
98,641
+25,000
+34% +$3.22M 4.79% 5
2019
Q1 		$9.95M Hold
73,641
– – 3.68% 5
2018
Q4 		$5.63M Sell
73,641
-8,000
-10% -$946K 3.5% 11
2018
Q3 		$8.7M Hold
81,641
– – 4.13% 8
2018
Q2 		$10.1M Buy
81,641
+9,200
+13% +$1.08M 3.89% 8
2018
Q1 		$8.07M Hold
72,441
– – 3.15% 12
2017
Q4 		$8.66M Sell
72,441
-19,700
-21% -$2.4M 3.05% 10
2017
Q3 		$12.9M Sell
92,141
-4,500
-5% -$611K 5.03% 5
2017
Q2 		$11.8M Sell
96,641
-28,000
-22% -$3.26M 4.47% 5
2017
Q1 		$15.1M Sell
124,641
-9,200
-7% -$1.19M 5.78% 5
2016
Q4 		$16.4M Buy
+133,841
New +$16.4M 7.38% 3

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

International Biotechnology Trust's ALXN Position: Q1 2021 in Review

International Biotechnology Trust sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 99,241 shares — an estimated $15.5M sold.

International Biotechnology Trust first reported a position in ALXN in Q4 2016 and held it in 17 quarters. The position peaked at $16.4M in Q4 2016. 754 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • International Biotechnology Trust reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • International Biotechnology Trust sold 99,241 Alexion Pharmaceuticals shares in Q1 2021, an estimated $15.5M.
  • International Biotechnology Trust first reported a position in Alexion Pharmaceuticals in Q4 2016 and held it in 17 quarters.
  • International Biotechnology Trust's Alexion Pharmaceuticals position peaked at $16.4M in Q4 2016.
  • 754 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on International Biotechnology Trust's 13F filing for Q1 2021, filed 17 May 2021.